Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DX 8951

Known as: DX-8951 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Background: DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier… Expand
  • figure 1
2005
2005
Purpose: To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks… Expand
  • figure 1
  • table 2
  • table 1
  • table 3
  • figure 2
2004
2004
DE-310, a new macromolecular prodrug, was designed to enhance the pharmacological profiles of a novel camptothecin analog (DX… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2002
2002
PURPOSE DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2001
2001
A new liquid chromatographic/mass spectrometric assay has been developed for the determination of DX-8951, a new anti-tumor drug… Expand
2001
2001
A sensitive high-performance liquid chromatographic (HPLC) method has been developed and validated for the determination of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2000
2000
PURPOSE To assess the feasibility of administering DX-8951f (exatecan mesylate), a water-soluble, camptothecin analog, as a 30… Expand
2000
2000
A sensitive quantitation of the lactone form and the lactone plus hydroxy-acid forms of DX-8951, a camptothecin derivative, in… Expand
Review
2000
Review
2000
Abstract: Exatecan mesylate (DX‐8951f) is a new hexacyclic camptothecin analogue with favorable attributes compared to topotecan… Expand
1997
1997
DX‐8951 is a novel water‐soluble derivative of camptothecin. We evaluated the effects of DX‐8951 on the growth of several… Expand